Tech Company Financing Transactions
Heat Biologics Funding Round
On 5/27/2010, Heat Biologics landed Series A funding from Brightspark.
Transaction Overview
Company Name
Announced On
5/27/2010
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Proceeds Purpose
The funds will primarily be utilized to expedite ongoing clinical trials of Heat's therapeutic vaccines to treat Non Small Cell Lung Cancer (NSCLC), a particularly lethal disease that claims approximately 160,000 lives in the U.S. each year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
627 Davis Dr. 400
Morrisville, NC 27560
USA
Morrisville, NC 27560
USA
Phone
Website
Email Address
Overview
Heat Biologics, a clinical-stage company, offers ImPACT, an adjuvant technology to identify oncology and infectious disease indications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeff Wolf
Chief Scientific Officer
Jeffrey Hutchins
Vice President
Gary Vinson
VP - Bus. Development
Lori McDermott
VP - R & D
Matthew Seavey
Browse more venture capital transactions:
Prev: 5/26/2010: PublicEarth venture capital transaction
Next: 5/27/2010: Encell Technology venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs